Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors
This Phase III trial will examine the efficacy of computerized cognitive training methods on perceived cognitive impairment in breast cancer…
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma
A phase 3 Study of Fixed Dose Combinations of Fianlimab and Cemiplimab Versus Relatlimab and Nivolumab in Participants with Unresectable…
IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) (PRISM-MEL-301)
A PHASE 3 RANDOMIZED, CONTROLLED STUDY OF IMC-F106C PLUS NIVOLUMAB VS NIVOLUMAB REGIMENS IN HLA-A*02:01 POSITIVE PARTICIPANTS WITH PREVIOUSLY UNTREATED…
A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma
A PHASE 2 AND PHASE 3 PERI-OPERATIVE TRIAL OF FIANLIMAB AND CEMIPLIMAB COMPARED WITH ANTI-PD1 ALONE IN PATIENTS WITH RESECTABLE…
Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
A Phase IV, Post-Authorization Safety Study to Investigate the Long-Term Safety of lutetium (177-Lu) vipivotide tetraxetan in Adult Participants with…
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician’s Choice New Hormonal Agents (EvoPAR-PR01)
A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of AZD5305 in Combination with Physician’s Choice New Hormonal Agents in Patients…
Pembrolizumab and Pemetrexed for Progressive Chordoma
A Phase II Study of Pembrolizumab and High-Dose Pemetrexed for the Treatment of Patients with Progressive Chordoma To determine objective…
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
An Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948…
A Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM (RESTORE)
A Phase II Double-blind, RandomizEd, Prospective, Placebo Controlled STudy of NanO2TM Combined With Radiation and Temozolomide in Patients With Newly-diagnosed…
A Randomized, Open-label, Phase 3 Study of MK-2870 in Combination With Pembrolizumab Compared to Pembrolizumab Monotherapy in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer With PD-L1 TPS Greater Than or Equal to 50%
Sacituzumab Tirumotecan in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death…